Pancreatic cancer is an aggressive cancer with a dismal prognosis. This is due to the
difficulty to detect the disease at an early and curable stage. In addition, only limited …

Despite increased investment and technological advancement, new drug approvals have
not proportionally increased. Low drug approval rates, particularly for new targets, are linked …

Transcription factors (TFs) control numerous genes that are directly relevant to many human
disorders. However, developing specific reagents targeting TFs within intact cells is …

The application of antibodies in cells was first shown in the early 1990s, and subsequently,
the field of intracellular antibodies has expanded to encompass antibody fragments and …

Targeted protein degradation (TPD) strategy harnesses the ubiquitin-proteasome system
(UPS) to degrade a protein of interest (POI) by bringing it into proximity with an E3 ubiquitin …

Intracellular antibodies have been deployed as powerful research tools for the last 20 years
for inhibition of proteins to convey specific information about protein function. Accordingly …

LMO2 is a transcription factor activated by chromosomal translocations or promoter
mutations in T cell leukaemia. It forms part of a multiprotein complex that has bipartite DNA …

The use of intracellular antibodies as templates to derive surrogate compounds is an
important objective because intracellular antibodies can be employed initially for target …

The RAS superfamily of small GTPases regulates major physiological cellular processes.
Mutation or deregulation of these small GTPases, their regulators and/or their effectors are …

Targeting hard-to-drug proteins, such as proteins functioning by protein-protein interactions
(PPIs) with small molecules, is difficult because of the lack of well-defined pockets. Fragment …